^
Association details:
| Biomarker: | BRCA2 mutation + RB1 deletion |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) + Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells
Published date:
01/04/2023
Excerpt:
This preclinical study assessed a combinatory treatment of the CDK4/6 inhibitor abemaciclib with PARP inhibitors talazoparib (TAL) in HCC1937 BRCA-mutated RB-deficient TNBC cells and TAL-resistant HCC1937-R cells...Our findings revealed that abemaciclib and TAL combination synergistically suppressed the growth of TNBC cells and overcame TAL resistance...These preliminary results suggest that the combination of abemaciclib and TAL could expand the use of these inhibitors in BRCA mutated and RB deficient TNBC patients and potentially overcomes PARP inhibitors resistance.
DOI:
10.1007/s00210-022-02375-4
